Moving between these two is mostly paperwork, not medicine. A new prescriber writes a new prescription after their own assessment, and continuity holds if the same molecule and strength resume without a break. What breaks instead is administrative: dose documentation, a restarted coverage review, prepaid money already spent, and the days between the last dose and the first new one.
The dose is the first thing to protect
Nobody who has spent four months escalating wants to begin again at the starting strength. Mochi addresses this in its FAQ, stating that a patient arriving from another program can continue at the same dose with documentation of the previous medication. Documentation is the operative word. A prescriber wants evidence rather than a self-report, so the step before canceling anything is to obtain records showing the drug, the strength, the frequency and the date of the most recent dose.
Moving the other way, into a brand product, the same evidence is needed but the arithmetic is harder. Ro determines eligibility from an online visit, quoting an answer within two days and a first dose in under a week when paying cash. A provider deciding where to restart wants the strength history, and where that history is a compounded preparation the numbers may not line up with the approved schedule.
Compounded and brand strengths are not interchangeable numbers
This is the single most underestimated part of a transfer. Mochi’s published compounded semaglutide runs from 0.22 mg to 2.67 mg weekly and its compounded tirzepatide from 2.2 mg to 16.6 mg weekly, with a month defined as four weekly doses. Approved products step through their own labeled schedules, and Ro’s posted cash pricing tracks those steps: the Wegovy pen from 0.25 mg through 2.4 mg plus a 7.2 mg high-dose option, the Zepbound KwikPen from 2.5 mg to 15 mg, the Wegovy pill from 1.5 mg to 25 mg, the Foundayo tablet from 0.8 mg to 17.2 mg.
Those ranges are not translations of each other. A compounded vial is also supplied at a concentration set by the preparing pharmacy, which is where administration errors have been documented: a published poison control case series recorded patients drawing up incorrect volumes after confusing units with milligrams. The conversion belongs to a clinician holding both records, and it should be written down rather than inferred from a marketing page.
It also helps to know which regulatory category is being left and which is entered. Compounded drugs are not FDA-approved and the agency does not review them for safety, effectiveness or quality, a point Mochi prints beside its compounded catalog. Programs showing the pathway, the strength range and the price on one page make a transfer easy to plan, and among flat-rate compounded services doing that are Henry Meds, Eden and FormBlends, whose side-by-side of these two companies is competitor-written and best read for the checklist rather than the conclusion.
| Transition step | What to ask the outgoing provider | What to ask the incoming provider | Paper to collect |
|---|---|---|---|
| Dose continuity | Written record of drug, strength, frequency, last dose date | Whether that record is enough to resume at the same strength | Visit note or prescription history |
| Pathway change | Concentration and units of any compounded vial supplied | How the strength converts to the new product | Pharmacy label or product sheet |
| Timing | Date the final shipment covers through | Stated interval from intake to first delivery | Shipment confirmation with dates |
| Money already paid | Treatment of unused months on a prepaid plan | Whether an equivalent prepaid term is required | Billing terms as displayed at purchase |
| Coverage | Copy of any approved prior authorization | Whether a new authorization must be filed | Insurer determination letter |
| Cancellation | The exact action that stops the recurring charge | Date the new recurring charge begins | Written cancellation confirmation |
Money that does not travel with you
Both companies sell prepaid blocks, and prepaid money is the least portable thing in this transaction. Ro’s membership is $39 for a first month and then $149 monthly, falling to $99, $89 or $74 across three, six and twelve month prepaid plans. Mochi’s is $79 monthly with a $39 introductory month, and prepaid terms of $199, $399 and $799. Ro’s returns page states that prescription products cannot be returned or refunded and that all sales are final, a common posture in mail-order pharmacy and worth reading before a multi-month purchase rather than after.
Mochi advertises cancel anytime with no hidden fees while noting that terms vary by state and that its promotional rate is not offered everywhere. Cancel anytime and refund anything are different promises. Asking which specific action ends billing, and getting the answer in writing, is the step that prevents an overlap month where two subscriptions run at once.
Coverage does not transfer, and the clock restarts
An approved prior authorization belongs to a prescriber and a plan, not to the patient in any portable sense. A new prescriber generally means a new submission. Mochi notes that insurers have 30 days to respond, and Ro quotes one to three weeks for its concierge to verify benefits and complete paperwork, with covered prescriptions sent to a retail pharmacy while cash orders ship directly.
That gap is the reason to start the second intake before the current supply runs out. Continuous treatment matters here. Randomized withdrawal work on both molecules found that stopping led to substantial weight regain, and an extension analysis of the semaglutide trial reported that participants regained most of the lost weight in the year after treatment ended. A two week administrative gap is not the same as discontinuation, but the direction of travel is clear enough that avoiding one is worth some planning.
Written guidance on changing products is one more thing to weigh before committing. Ro and Hims and Hers describe their own transfer handling inside the signup flow, Henry Meds documents an intake for arriving patients, and HealthRX keeps a public page on switching GLP-1 medications that sets out the dose-documentation and timing questions ahead of a visit. Reading a provider’s transfer instructions before canceling the current subscription is cheaper than discovering them halfway through a supply gap.
Frequently asked questions
Will a new provider make you restart at the lowest dose?
Not necessarily. Mochi states it can continue an existing dose with documentation of the previous medication, and prescribers generally prefer continuity where records support it. Without paperwork, a cautious clinician may restart lower, which is a good reason to request records before ending the current subscription.
Does moving from a compounded product to a brand one need a new titration?
Often it needs an adjustment rather than a full restart. The strength ranges published for compounded preparations do not map onto the approved dosing schedules, so a prescriber has to decide where the equivalent point sits. That determination should be made from the pharmacy label and visit records, not estimated by the patient.
What happens to an unused prepaid membership?
It depends on the terms accepted at purchase and on state law. Both companies sell three, six and twelve month blocks at reduced monthly rates, and a prepaid discount only pays off if treatment lasts the term. Reading the cancellation section before buying a long block is the cheapest protection available.
Can both memberships run at once during a transfer?
They can, and that is the usual cost of avoiding a supply gap. One overlapping membership month is a smaller problem than an interrupted escalation for most people, but it should be a deliberate choice with a date attached rather than something discovered on a card statement.
Does an insurance approval move with the patient?
Generally not. Authorizations are tied to a prescriber and a specific product under a specific plan, so a new prescriber usually files again. Keeping a copy of the original determination letter speeds the second submission, because it documents the clinical criteria the plan already accepted once.
